【作 者】:网站采编
【关键词】:
【摘 要】:基于优异的数据,帕博利珠单抗已向国家药品监督管理局递交上市申请,并被纳入优先审评名单,相信帕博利珠单抗即将惠及中国初治头颈部鳞癌患者,让
基于优异的数据,帕博利珠单抗已向国家药品监督管理局递交上市申请,并被纳入优先审评名单,相信帕博利珠单抗即将惠及中国初治头颈部鳞癌患者,让长期生存的梦想照进现实。
?
参考文献 |
[1]Bray F, Ferlay J, Soerjomataram I, et al. Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwise for 36 Cancers in 185 Countries. CA Cancer J Clin. 2018; 0:1-31. |
[2]郭晔, 白春梅, 李志铭, et al. 复发转移性头颈部鳞癌的免疫治疗进展[J]. 肿瘤预防与治疗, 2019, 032(007):572-579. |
[3]?Argiris A , Li Y , Forastiere A . Prognostic factors and long-term survivorship in patients with recurrent or metastatic head and neck cancer (HNC): An analysis of two Eastern Cooperative Oncology Group (ECOG) randomized trials[J]. Journal of Clinical Oncology Official Journal of the American Society of Clinical Oncology, 2004, 22(14_suppl):5514. |
[4]郭晔. 头颈部肿瘤的免疫治疗[J]. 中国癌症杂志, 2017, 27(006):459-462. |
文章来源:《肿瘤》 网址: http://www.zlzzs.cn/zonghexinwen/2020/1112/666.html